Novo Nordisk is involved in diving after the Wegovy-Maker is reduced to the entire year instructions

Danish pharmaceutical giant Novo Nordsk On Tuesday, she appointed her new CEO, while simultaneously reduced her directives in the entire year, noting the weakest growth expectations for obesity drugs in Wegoz in the main American market.

The drug maker said that the veteran veteran company Mike Mike Doustdar will take over as president and executive director yet Surprise extinguishing In May from Lars Fergard Jurgen. The date is to consider August 7.

The shares decreased up to 26 % before reducing the losses slightly for 20 % trading by 1:26 pm London time (8:26 am East time).

The company said it is now expecting 8 % sales of the entire year to 14 % in fixed exchange rates, a decrease from a previous goal of 13 % to 21 %.

An annual operating profit growth expects from 10 % to 16 % against the previously estimated target from 16 % to 24 %, and also at fixed exchange rates.

Novo Nordsk said on Tuesday that the low view was driven by the expectations of sales growth in the second weakest in the treatment of weight loss in Wegovy and OzemPic diabetes treatment.

“For Wegovy in the United States, sales forecast reflects the continuous use of the GLP-1 vehicle, and the market expansion is slower than expected,” he added in a statement.

It comes after the company reduced its expectations for 2025 in May, as it is I mentioned less than expected Sales in the first quarter. The company is scheduled to report its sales in the second quarter on August 6.

Doustdar, who joined Novo Nordisk in 1992, has occupied many executive functions throughout Europe and Asia, which recently worked as an executive deputy for international operations.

In a statement accompanying the announcement, the Chairman of the Board of Directors described Helj Lund Mike Dosdar as “the best person to lead Novo Nordisk during the next growth phase.”

“I have reached this role with a sense of urgency, the concentration of the laser on high performance, and a fierce design on Novo Nordisk to aim to the highest of what happened, and to connect many of the patients they need,” Dosdar added.

The giant Pharma, which is based in Copenhagen, was fighting the most soft Wegov sales, as a competition from compound drug makers rose in the wake of the ruling on drug lack in medicines.

The price of its share decreased more than 42 % this year.

However, she previously mentioned that she expects these pressures to give up in the second half of the year, as the gradual disposal of the availability of counterfeit drugs has been given up.

Meanwhile, the company struggled to get rid of negative feelings after a series of Disappointed experimental results Its candidate from the next generation of CAGRISEMA drug candidate amid the competition in the market.